Elacytarabine - 10mM in DMSO , RNA inhibitor, CAS No.188181-42-2, RNA inhibitor

CAS: 188181-42-2 Cat. No.: E654970 Formule: C27H45N3O6 Poids moléculaire: 507.7 PubChem CID: 6438895
DISPONIBLE À COMMANDE
QUALITÉ & PURETÉ 10mM in DMSO
Storage
Store at -80°C
Shipped In
Dry ice packs + Cold packs
★
Taille
USA
Allemagne (EU)*
Prix
Qté
1ml
E654970-1ml
Sur commande · 8–12 semaines
246,90$US
Enter a quantity for the sizes you want to add.

Vue d’ensemble

Elacytarabine (CP 4055) is a lipid-conjugated derivative of the nucleoside analog cytarabine. Elacytarabine (CP 4055) is an antineoplastic agent with cytotoxicity in solid tumors.

Spécifications

Spécifications et pureté
10mM in DMSO
Mécanismes biochimiques et physiologiques
Elacytarabine (CP 4055) is a lipid-conjugated derivative of the nucleoside analog cytarabine. Elacytarabine (CP 4055) is an antineoplastic agent with cytotoxicity in solid tumors.
Conditions de stockage de stockage
Store at -80°C
Expédié en
Dry ice packs + Cold packs
Ce produit nécessite l'expédition en chaîne froide. Les services terrestres et autres services économiques ne sont pas disponibles.
Type d'action
INHIBITOR
Mécanisme d'action
RNA inhibitor
Noms et identifiants
Isomères SMILES
CCCCCCCC/C=C/CCCCCCCC(=O)OC[C@@H]1[C@H]([C@@H]([C@@H](O1)N2C=CC(=NC2=O)N)O)O
CAS alternatif
101235-34-1,188181-42-2
PubChem CID
6438895
Termes d'entrée MeSH
5'-oleoyl cytarabine;5'-oleoyl cytosine arabinoside;5'-oleyl-ara-C;CP 4055;CP-4055;CP4055;ELACYT;elacytarabine
Poids moléculaire
507.7

Données avancées

Certificats (CoA, COO, BSE/TSE et tableau d'analyse)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Calculateurs de solution
Avis

Avis des clients

Application Protocols

No assay-specific, lot-validated protocols are provided for this item. The following general practices are commonly used in small-molecule research and screening; adapt to your system.

  • Stock solution (general):

    • Prepare in dry DMSO (e.g., 10 mM). Vortex and, if necessary, brief sonication. Filter through 0.22 µm PTFE for sterile applications. Record final solvent percentage targets for assays.
  • Cell-based assays (general guidance):

    • Dose-response curves across multiple logs; maintain constant vehicle concentration (e.g., 0.1–0.5% DMSO). Include cytarabine as a mechanistic comparator if studying prodrug activation.
    • For transporter/uptake studies, consider pre-treatments or inhibitors of nucleoside transporters and esterases; measure intracellular ara-C and triphosphate levels by LC–MS where applicable.
  • In vitro stability assays:

    • Incubate in buffer, serum, or microsomes at 37°C; sample at defined intervals; quench and analyze by LC–MS to quantify parent and cytarabine formation.
  • Controls and documentation:

    • Include vehicle controls, matrix blanks, and stability controls (t0/tfinal). Archive preparation records, lot numbers, and storage conditions to ensure reproducibility.

Note: The above are literature/practice suggestions and are not product-specific validated methods.

Biological Roles

Note: Information below reflects general biochemical context from the literature and does not imply therapeutic use.

  • Mechanistic role (literature):

    • Elacytarabine is a 5′-O-elaidate ester of cytarabine, functioning as a lipophilic proagent. Cellular esterases can hydrolyze the ester to release cytarabine (ara-C), a deoxycytidine analog that is phosphorylated intracellularly to its triphosphate, which can be incorporated into DNA and impair DNA synthesis.
  • Transport and disposition (literature):

    • The elaidic chain increases membrane partitioning and can reduce reliance on equilibrative/concentrative nucleoside transporters for cell entry compared with cytarabine. Lipidation may modulate plasma protein binding, distribution, and susceptibility to deamination versus hydrolysis pathways.
  • Metabolic fate (literature):

    • Primary biotransformation via ester hydrolysis (chemical or enzymatic) yielding cytarabine and elaidic acid. Subsequent cytarabine metabolism follows known kinase activation and deamination routes.
  • Utility in biology:

    • Probe for studying relationships between lipophilicity, transporter independence, and prodrug activation in nucleoside analogs.
    • Tool compound in assays assessing esterase activity and in vitro stability across matrices (buffer, plasma, microsomes).
Buffer Applications

This compound is not a buffering agent and is not used to prepare defined pH buffer systems. For experimental use, it is typically formulated as an organic stock (e.g., DMSO) and diluted into assay buffers.

  • Practical notes:
    • When dosing into aqueous buffers, pre-dilute organic stocks stepwise and include compatible co-solvents or carriers (e.g., 0.1–1% DMSO, small % ethanol, or non-ionic surfactants) to avoid precipitation.
    • Maintain consistent final solvent percentages across controls and treated samples to avoid confounding effects in biochemical or cell-based assays.
Green Alternatives

As a lipophilic small molecule, the main environmental lever is solvent and formulation choice rather than substitution of the active itself.

  • Greener solvent strategies (general guidance):

    • Prefer ethanol or 2-propanol for lower-to-moderate concentration stocks when assay-compatible, minimizing use of high-boiling aprotics (DMSO/DMF).
    • For aqueous dosing, use cyclodextrin inclusion complexes or lipid emulsions to reduce organic solvent fractions.
    • Employ microdosing formats to limit total solvent volumes in high-throughput screens.
  • Comparison of common vehicles (general, literature):

    | Vehicle | Greenness/Regulatory perception | Solubilization power | Notes | |---|---|---|---| | Ethanol | Preferred bio-based solvent | Moderate | Evaporates readily; watch for precipitation on dilution | | 2-Propanol | Acceptable | Moderate | Similar to ethanol, slightly less polar | | DMSO | Less green (sulfur-containing, high b.p.) | High | Gold standard for stocks; minimize final % in assays | | PEG400 | Acceptable | Moderate–High | Viscous; can reduce volatility and inhalation exposure |

  • Operational practices:

    • Aliquot to reduce waste from repeated thawing.
    • Use amber vials and inert headspace to extend shelf life and reduce decomposition, thereby minimizing discard rates.
Pharmaceutical Uses

No clinical or therapeutic claims are made for this catalog item. The following relates to formulation science considerations in research settings (literature/general):

  • Role in formulation research:

    • As a lipophilic nucleoside ester, elacytarabine is a model for studying how lipidation affects delivery systems (e.g., lipid emulsions, micelles, liposomes) and aqueous compatibility.
    • Its hydrophobicity allows exploration of reduced reliance on nucleoside transporters by enabling membrane partitioning in vitro.
  • Excipients/vehicles commonly evaluated (research context):

    • Ethanol/propylene glycol or PEG400 co-solvent systems; lipid-based carriers; cyclodextrin complexes to increase apparent solubility.
  • Analytical/formulation considerations:

    • Track conversion to cytarabine during storage and in dissolution media; validate stability-indicating methods (e.g., LC–UV/MS) to separate parent and released ara-C.
    • Control oxygen exposure and light to limit potential oxidation of the unsaturated C18 chain during formulation studies.
Physical Properties
  • Item-specific specifications: Not specified for this item; refer to CoA/Spec Sheet.

  • Literature/general reference values (for context; not lot specifications):

    • Molecular formula: C27H45N3O6 (literature)
    • Molecular weight: ~507.67 g/mol (literature)
    • Physical state: Typically a lipophilic solid; appearance varies with form and hydration (literature).
    • Solubility profile: Readily soluble in polar aprotic organic solvents (e.g., DMSO, DMF); sparingly soluble to practically insoluble in water due to the C18 chain; soluble in ethanol and isopropanol to moderate extents (literature). For assay stocks, DMSO is commonly used (literature).
    • Partition behavior: Significantly increased lipophilicity relative to cytarabine; cLogP expected to be high owing to the fatty acid ester (qualitative, literature).
    • UV characteristics: Nucleobase absorbs in the 260–280 nm region; specific extinction coefficients are matrix-dependent (literature; not specified for this item).
    • Stability considerations: Ester linkage susceptible to hydrolysis under strong acidic or basic conditions; trans-alkenyl chain is prone to autoxidation upon prolonged exposure to air/heat/light (literature).
Quality and Grades
  • Item-specific quality info (from Product Data):

    • Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet.
    • Research Use Only: Yes (per Product Data: For research use only).
  • Interpreting grade and documentation:

    • In the absence of a stated grade, consult the Certificate of Analysis (CoA) and Specification Sheet for assay, related substances, water content, and residual solvent limits. These documents provide lot-specific acceptance criteria and analytical methods.
    • For small-molecule screening libraries, typical quality attributes include HPLC/UPLC purity, identity confirmation by MS/HRMS and NMR, and controlled counter-ions/solvates. UV trace and low non-volatile residue are important when the compound is used in bioassays or analytical method development (general guidance).
  • Stabilizers and additives:

    • No stabilizer is specified for this item. If a stabilizer or salt form is needed for your workflow, contact Technical Support for availability or custom formulation.
  • Practical recommendations:

    • Verify identity upon receipt if mission-critical (e.g., LC–MS single-ion monitoring for [M+H]+ ~508, literature) and confirm purity under your chromatographic conditions.
    • If you require low-oxygen handling (to limit possible unsaturated-chain oxidation), consider storing under inert gas after aliquoting, and track retest dates from the CoA.
Reaction and Applications

This product is a bioactive small molecule standard rather than a general-purpose synthetic reagent. Its principal laboratory applications are in chemical biology and ADME/stability studies rather than as a stoichiometric reagent.

  • Research applications (literature/general):

    • Prodrug mechanistic studies: Model for evaluating how long-chain 5′-O-acylation of nucleosides alters membrane permeability, transporter dependence, and intracellular activation to ara-C (after esterase-mediated hydrolysis).
    • Uptake/efflux investigations: Useful probe to examine nucleoside transporter–independent entry versus lipophilic diffusion and to study ABC transporter interactions.
    • Metabolic stability: Assessment of ester hydrolysis kinetics in plasma, microsomes, and cellular lysates; identification of active metabolite (cytarabine) formation.
    • Formulation science: Screening of lipid-, cyclodextrin-, or nanoparticle-based delivery systems for hydrophobic nucleoside esters.
  • Analytical use:

    • Reference standard for LC–MS method development: monitor parent → cytarabine conversion; establish multiple reaction monitoring (MRM) transitions; evaluate matrix effects across biological matrices.
  • Not typically used for: Classical named organic reactions, catalysis, or polymer synthesis. For synthetic transformations, see the “Synthetic Utility” section for context on related chemistry with lipidated nucleosides.

Reaction Conditions

Not typically used as a reagent. The following conditions are generic, literature-based guidance relevant to analytical/stability manipulations of elacytarabine and related esters, not recommendations for manufacturing.

  • Ester hydrolysis (stability studies, literature):

    • Base-catalyzed: Aqueous NaOH or K2CO3 in methanol/water at ambient temperature can rapidly hydrolyze the 5′-O-ester to release cytarabine; monitor by LC.
    • Acid-catalyzed: Dilute mineral acid in aqueous organic media at mild heat accelerates hydrolysis; avoid if preserving parent.
    • Enzymatic: Porcine liver esterase or other carboxylesterases in phosphate buffer (pH ~7.4) at 37°C to model bioconversion.
  • Oxidation control (literature/practice):

    • Protect from air and light; inclusion of antioxidants (e.g., BHT) is sometimes evaluated in method development. No stabilizer is specified for this item.
  • Stock preparation (practical):

    • Dissolve in anhydrous DMSO, filter through 0.22 µm PTFE if needed. Avoid prolonged warming. Aliquot and store at ultra-low temperatures to limit degradation.

All numerical conditions above are general literature practices for nucleoside esters; verify and optimize for your system.

Safety and Handling
  • Item-specific hazard data (from Product Data):

    • GHS Classification: Not specified for this item; refer to SDS.
    • Signal Word: Not specified for this item; refer to SDS.
    • H-Statements: Not specified for this item; refer to SDS.
    • Pictograms: Not specified for this item; refer to SDS.
  • General laboratory handling guidance (literature/practice; defer to SDS as authority):

    • Treat as a bioactive small molecule and potential cytotoxic nucleoside analog proagent. Avoid inhalation, ingestion, and skin contact. Use in a chemical fume hood.
    • PPE: Lab coat, safety glasses, and appropriate chemical-resistant gloves (e.g., nitrile). Consider double-gloving and using disposable sleeve covers when weighing.
    • Avoid generating dust/aerosols. Prepare solutions in closed vessels; wipe surfaces after use.
    • Incompatibilities: Avoid strong acids/bases that can catalyze ester hydrolysis; avoid strong oxidizers that may react with the unsaturated C18 chain (literature).
    • First aid (overview): If on skin or in eyes, rinse with water for at least 15 minutes and remove contaminated clothing; if inhaled, move to fresh air; if ingested, rinse mouth. Seek medical attention in all exposure cases. Provide the SDS to responders.
    • Waste: Collect spills with inert absorbent. Dispose as hazardous chemical waste in accordance with institutional and local regulations.
    • Transport/storage: Keep tightly closed, protected from light and air to minimize oxidation; maintain recommended ultra-low temperature.
Solvent Selection

Elacytarabine is markedly more lipophilic than cytarabine due to the C18:1 trans fatty acid ester, guiding solvent choice toward aprotic organics for stock solutions and assay dosing.

  • Practical solvent recommendations (literature/practice):

    • DMSO: Preferred for high-concentration stocks (e.g., 10–50 mM in screening workflows). Good chemical stability at low temperature; miscible with aqueous buffers upon dilution.
    • DMF: Alternative to DMSO when required by assay components; similar solubilizing power.
    • Ethanol/IPA: Useful for lower concentration stocks or co-solvent strategies; verify assay tolerance.
    • Aqueous buffers: Poor intrinsic solubility expected; use co-solvents, surfactants (e.g., Tween 80), cyclodextrins, or lipid-based vehicles if aqueous delivery is required (literature).
  • Polarity/miscibility profile (qualitative, literature):

    • Non-volatile, polar-aprotic–soluble; immiscible with water at high concentrations; miscible with most organic solvents.
  • When to choose alternatives:

    • If minimizing DMSO content is critical, consider ethanol or PEG400 co-solvent systems, or formulate with liposomes/mixed micelles to enable aqueous dosing.
  • Small comparison (general):

    • DMSO: Highest solvency; potential assay interference at >0.5–1% v/v.
    • Ethanol: Lower solvency; better volatility and easier removal.
    • Aqueous + surfactant: Facilitates biological dosing; may complicate analytics.
Storage and Reconstitution
  • Item-specific storage and shipping (from Product Data):

    • Storage Conditions: Store at -80°C.
    • Shipped In: Dry ice packs + Cold packs.
  • Reconstitution (general guidance; not a specification):

    • Dissolve in anhydrous DMSO to prepare a concentrated stock appropriate for your application. If aqueous dosing is required, perform gradual dilution into buffer with gentle mixing; consider co-solvents or carriers (e.g., ethanol, PEG400, cyclodextrins, or non-ionic surfactants) to avoid precipitation.
    • Use amber vials and minimize headspace oxygen to reduce potential oxidation of the unsaturated chain during storage.
  • Aliquoting and stability (general best practices):

    • Prepare single-use aliquots to avoid repeated freeze–thaw cycles. Thaw on ice and return unused portions promptly to -80°C.
    • Store solutions at ultra-low temperature; assess stability periodically by a stability-indicating LC method to monitor parent integrity and potential conversion to cytarabine.
  • Shelf life and specifications:

    • No specific retest date or shelf life is provided here. Consult the CoA/Spec Sheet for lot-specific guidance.
  • Safety note:

    • Label all aliquots clearly with concentration, solvent, and date. Handle within a fume hood and dispose of waste according to institutional policies.
Structure and Identity

Brief intro: Elacytarabine (CP-4055) is a long-chain fatty acid ester proagent of the nucleoside analog cytarabine (ara-C), designed to increase lipophilicity and alter uptake/activation profiles.

  • Item-specific (from Product Data):

    • SKU: E654970
    • Product Name: Elacytarabine
    • CAS: 188181-42-2
    • Storage: Store at -80°C
    • Shipped in: Dry ice packs + Cold packs
    • Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet.
    • Appearance: Not specified for this item; refer to CoA/Spec Sheet.
  • Literature/Computed identity (for reference; not a specification of this lot):

    • Common synonym: CP-4055; ara-C 5′-elaidate; cytarabine 5′-elaidic acid ester (literature)
    • Molecular formula: C27H45N3O6 (literature)
    • Molecular weight: ~507.67 g/mol (literature)
    • PubChem CID: 6438895 (literature)
    • SMILES: Not specified for this item; refer to CoA/Spec Sheet.
    • InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
  • Structural features (descriptive, literature):

    • Core: 1-β-D-arabinofuranosyl cytosine (cytarabine) nucleoside scaffold.
    • Functionalization: 5′-O-esterification with elaidic acid (trans-octadec-9-enoic acid), introducing a C18:1 trans unsaturated aliphatic chain.
    • Functional groups: Nucleobase (cytosine), furanose sugar, primary ester linkage, secondary alcohols, amide-like heterocycle in base.
    • Stereochemistry: β-N-glycosidic linkage; multiple sugar stereocenters retained from ara-C; the C18 chain contains a trans double bond (E-geometry, literature).
Synthetic Utility

Although sold as a finished small molecule for research, the chemistry underlying elacytarabine is instructive for nucleoside prodrug design.

  • Functional groups and reactivity (literature):

    • Primary alcohol at 5′ masked as an ester with elaidic acid; the ester is cleavable under acidic/basic or enzymatic conditions.
    • Retained secondary alcohols on the sugar ring; nucleobase exocyclic amine (cytosine) is present.
  • Retrosynthesis (conceptual):

    • Cytarabine (ara-C) 5′-OH + elaidic acid (or activated derivative, e.g., acid chloride or mixed anhydride) → elacytarabine via esterification.
    • Protection strategies may be used to preserve 2′/3′ hydroxyls if selectivity is an issue; acylation at 5′ is typically favored with suitable conditions.
  • Reference value in method development:

    • Serves as a benchmark substrate for optimizing selective acylations of nucleosides, assessing coupling reagents (e.g., DCC/DMAP, EDCI/DMAP) and solvent systems (e.g., dichloromethane, pyridine, or polar aprotics). While not itself a reagent, it helps validate synthetic and analytical workflows for lipidated nucleoside esters.
  • Derivatization potential:

    • Hydrogenation of the elaidic double bond (model studies) or chain-length/unsaturation variation provides a platform to probe structure–property relationships.
Target Specificity

Not applicable. This product is a small-molecule nucleoside ester, not an antibody or affinity reagent. No antigen, clone, isotype, or species reactivity information applies.

  • For biological context, see “Biological Roles” for general mechanisms and “Pharmaceutical Uses” for formulation-oriented notes.

Souhaitez-vous que nous vous envoyions un message lorsque des réductions seront disponibles?

Me rappeler plus tard

Merci ! Veuillez vérifier votre boîte de réception e-mail pour confirmer.

Oups ! Les notifications sont désactivées.